Zydus Cadila launched Ujvira, the first antibody drug conjugate (ADC)

Zydus Cadila launched Ujvira, a drug used for the treatment of breast cancer.
The company has launched the first antibody-drug conjugate (ADC) biosimilar and very effective medicine for treating both early and advanced HER2 positive breast cancer, under the brand name Ujvira, Zydus Cadila.
The drug is being offered at Rs 32,495 for a 100 mg vial.
Zydus Cadila said HER2 positive breast cancer is measured in an antagonistic form and founds 20 to 25 percent of all breast cancers. Trastuzumab Emtansine ADC biosimilar is a developmental finding due to its difficulty in manufacturing and parallel assays.

Source: moneycontrol

Comments

Test name February 19, 2016 Reply

There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration in some form, by injected humour, or randomised words which don't look even slightly believable. If you are going to use a passage of Lorem Ipsum, you need to be sure there isn't anything embarrassing hidden in the middle of text.

Test name February 19, 2016

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Test name February 19, 2016Reply

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Leave a Comment